ONCOS-102 is one of the most promising oncolytic viruses with >200 patients treated. Targovax stock has been under pressure for years after equity offerings at fairly low pricing, but has been making a strong move recently, quite without many investors taking notice. Norwegian Biotech especially in the field of cancer immunotherapy may be ready for a new round of interest after the recent news about Vaccibody partnering with Genentech.
עסקה פעילה
⋅
Positive news last night from Targovax, webcast in 30 minutes from now
Targovax announces impressive objective responses as well as effects on non-injected lesions in ONCOS-102 trial in anti-PD1 refractory melanoma patients · Tumor responses observed in 7 out of 20 evaluable patients, resulting in best objective response rate (ORR) of 35% · Systemic effects observed in multiple patients, including two examples where a non-injected lesion completely regressed · An online presentation by Targovax's management will take place at 10:00 CET 2 December 2020 (details below)
עסקה פעילה
⋅
Nice bounce today, stay in the trade
עסקה פעילה
⋅
Targovax received FDA Fast track designation for Oncos 102!